ChiCTR2100049315
正在进行
/
/
/
2021-07-30
/
/
Borderline Personality Disorder; Pervasive dysregulation (e.g., behavioral, emotional, relational, etc.) with functional impairment in at least one domain (e.g., work, family, relationship, etc.)
DBT in Hong Kong Mental Health Community Setting
The Effectiveness of Dialectical Behavior Therapy in a Mental Health Community Setting in Hong Kong
Dialectical Behavior Therapy (DBT) is an evidence-based treatment for individuals with symptoms of different psychiatric diagnoses (e.g., Cristea et al., 2017), particular those at risks for suicide or parasuicidal behavior (e.g., DeCou et al., 2019; Stanley et al., 2007) and those reporting emotion dysregulation (e.g., Kells et al., 2020). A transdiagnostic treatment that meets the needs of clinical populations at various risk levels can potentially mitigate the associated high cost to the health system as a whole. Considering the various components of DBT, establishment of a standard DBT program can be a multi-phasic project. Stand-alone DBT skills training groups have been found effective in reducing symptoms of mental health disorders (Valentine et al., 2014) and strengthening emotion regulation (Kells et al., 2020). Therefore, this study serves as a pilot and focuses on the effectiveness of skills training groups. Preliminary data collected will not only inform the projects subsequent phase(s) of expansion into a standard DBT program but also shed light on the implementation of DBT in an outpatient community setting in Hong Kong.
单臂
Ⅲ期
N/A
N/A
Lump sum grant
/
50
/
2021-07-14
2026-03-31
/
- Aged 18 years or up; - Speak, read, and write Chinese; - Meet diagnostic criteria of Borderline Personality Disorder; OR show traits of pervasive dysregulation (e.g., behavioral, emotional, relational, etc.) with functional impairment in at least one domain (e.g., work, family, relationship, etc.); - Present treatment needs related to Stage 1 treatment targets as defined in DBT, such as life-threatening concerns, therapy-interfering behaviors, quality-of-life-interfering behaviors; - Show elevation on screening measures such as the Borderline Symptom List 23 (BSL-23).;
请登录查看- Present with active psychosis without insight; - Demonstrate sub-average intelligence; - Decline to commit on Stage 1 treatment targets; that is, targets related to areas such as life-threatening concerns, therapy-interfering behaviors, quality-of-life-interfering behaviors; - Concurrently receive other psychological services.;
请登录查看新生活精神康復協會
/
新生活精神康復協會的其他临床试验
香港新生活精神康復協會的其他临床试验
最新临床资讯
-
飞眸医疗首例人体临床试验(FIH)成功开展,国产飞秒屈光设备竞逐540亿屈光市场
动脉网-最新2026-09-10
-
和铂医药:超长效靶向TSLP抗体哮喘二期临床取得阳性结果,三期临床已启动
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
动脉网-最新2026-09-09
-
药明康德2026-09-09
-
一度医药2026-09-08
-
阿斯利康中国2026-09-08
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-09-26
-
2026-09-26
-
2026-09-26
-
摩熵咨询 20 8
-
摩熵咨询 20 11
-
摩熵咨询 34 56
-
颁布机构:国家药品监督管理局 2026-09-10
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构:国家医保局 2026-07-31
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-09-28
-
2026-09-26
-
2026-09-26
-
摩熵咨询 35 71
-
摩熵咨询 28 60
-
摩熵咨询 34 42
-
颁布机构:国家市场监督管理总局 2026-09-18
-
颁布机构:国家市场监督管理总局 2026-09-17
-
颁布机构:国家市场监督管理总局 2026-08-10
